RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting clinical trials that explore combination therapies involving novel antibody-drug conjugates (ADCs), specifically, RC88 and RC108, and the PD-1 inhibitor sintilimab injection, TYVYT. As per the agreement, Innovent Biologics will supply […]
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China suffering from difficult-to-treat cancers. The two parties plan to expedite the development and commercialization of a couple of important clinical stage oncology assets of Sanofi, which are SAR408701 (tusamitamab ravtansine; […]
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small cell lung cancer (NSCLC). Lilly has been issued a complete response letter (CRL) for the BLA for the PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy. The US pharma […]
Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]
